Back

CMR-based assessment of left ventricular hemodynamics in obstructive hypertrophic cardiomyopathy treated with septal reduction therapy

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Prognostic imaging in hypertrophic cardiomyopathy and amyloidosis Flow Imaging ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Ms Mengdi Yu

Sichuan (China)

5 More presentations in this session

Presentation thumbnail
Assessment of left ventricular function measured with cardiac MRI feature tracking predicts heart failure events in childhood hypertrophic cardiomyopathy
Doctor X. Chen (Beijing, CN)
Abstract Slides
Presentation thumbnail
The PA/Ao ratio as a predictor for adverse outcomes in light-chain vs. transthyretin cardiac amyloidosis
Mr L. List (Vienna, AT)
Abstract Slides
Presentation thumbnail
Novel thresholds for all-cause mortality risk stratification in hypertrophic cardiomyopathy using cardiac magnetic resonance- late gadolinium enhancement
Miss S. Arshanapalli (London, GB)
Abstract Slides
Presentation thumbnail
Comprehensive cardiovascular magnetic resonance for evaluating structural myocardial changes in patients with hypertrophic obstructive cardiomyopathy treated with the first myosin inhibitor
Doctor L. Seuthe (Cologne, DE)
Abstract Slides
Presentation thumbnail
Cardiovascular magnetic resonance late gadolinium enhancement risk score for mortality in hypertrophic cardiomyopathy: the HCM-LGE risk score
Doctor J. Florence (Paris, FR)
Abstract Slides

Access the full session

Session thumbnail
Prognostic imaging in hypertrophic cardiomyopathy and amyloidosis
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Non-invasive assessment of left ventricular hemodynamic forces in hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1893 in patients with obstructive hypertrophic cardiomyopathy: a randomized, double-blind, placebo-controlled phase 1 trial
thumbnail
Congress Presentation
Unfavorable systemic and coronary hemodynamic profile of left ventricular hypercontractile phenotype in hypertrophic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources